CORE
🇺🇦
make metadata, not war
Services
Research
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
3 research outputs found
Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects
Author
American Diabetes Association
Farxiga®
+3 more
Forxiga®
Onglyza®
Wertheimer AI
Publication venue
'Wiley'
Publication date
Field of study
No full text
Crossref
Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
Author
Farxiga® (dapagliflozin)
Glucophage® (metformin)
+7 more
Invokana® (canagliflozin)
Januvia® (sitagliptin)
Jardiance® (empagliflozin)
Nesina® (alogliptin)
Onglyza® (saxagliptin)
Robert M. Guthrie
Tradjenta® (linagliptin)
Publication venue
'Informa UK Limited'
Publication date
Field of study
No full text
Crossref
Combination therapy for type 2 diabetes: dapagliflozin plus metformin
Author
American Diabetes Association
Chaplin S
+4 more
Farxiga® (dapagliflozin)
Jingbo Hu
Wright EM
Xueying Tan
Publication venue
'Informa Healthcare'
Publication date
Field of study
No full text
Crossref
No full text
No full textNo full text